Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

V. Peter Collins(University of Cambridge), Sally Stenning(Medical Research Council), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Danita M. Pearson(University of Cambridge), Rhian Gabe(Cancer Research UK), Koichi Ichimura(Hiroshima City Asa Citizens Hospital), Ray Chan(University of Cambridge), Ying Di(University of Cambridge), Michael Brada(University of Liverpool)

Acta Neuropathologica Communications

June 20, 2014

10.1186/2051-5960-2-68

Cited by 34

Related Papers

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

|The Lancet|2009|1.5k

Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

|The Lancet|2009|1.1k

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

|Nature Genetics|2009|788

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

|The Lancet|2007|570

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

|The Lancet|2011|420